Home > En > The use of 64Cu-ATSM for the diagnosis of tumor hypoxia: questions on the (...)

The use of 64Cu-ATSM for the diagnosis of tumor hypoxia: questions on the meaning of tumor uptake.

Monday 16 December 2013

Two papers which will be published in the next issue of the Journal of Nuclear Medicine report on the mechanism of tumor uptake of 64Cu-ATSM and the physio-pathological meaning of this uptake. They showed, in a preclinical study, that biodistribution of 64Cu-ATSM is essentially identical to that of its precursor, 64Cu-acetate. The authors wonder about the uptake mechanism of the two radiotracers which could be at least partially related to copper by itself rather than to its carrier molecule. This discussion could apply to 64CuCl2, which binds to tumors through a copper transporter, CTr-1 and which seems to reflect tumor aggressiveness.
Hueting R, et al. A comparison of the behavior of 64Cu-acetate and 64Cu-ATSM in vitro and in vivo. J Nucl Med 2014;55:1-7
Dearling JLJ, Packard AB. On the destiny of (copper) species. J Nucl Med 2014;55.